Adrien Chan Sui Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Adrien Chan Sui Ko has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Candellier
Department of Nephrology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
2 shared publications Claire Andrejak
Department of Pneumology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
2 shared publicationsJean-Luc Schmit
Department of Infectious Diseases, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
2 shared publicationsJean-Philippe Lanoix
Department of Infectious Diseases, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
2 shared publicationsMarie Mercier
Department of Pneumology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
2 shared publicationsCedric Joseph
Department of Infectious Diseases, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, 80054, France
1 shared publication
Latest Publications
- Open Access
- 18 August 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 6645-6651
No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19
Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58– 1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.
- 18 August 2022
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 15, 6645-6651
Open AccessNo Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19
Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58– 1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.
- Open Access
- 5 March 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 220-223
Number of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients
- 5 March 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 118, 220-223
Open AccessNumber of initial symptoms is more related to long COVID-19 than acute severity of infection: a prospective cohort of hospitalized patients